Cytarabine and Ferric Carboxymaltose (Fe+3) Increase Oxidative Damage and Alter Serotonergic Metabolism in Brain.
BACKGROUND & OBJECTIVE
The purpose of this study was to measure the effect on brain biomarkers after treatment with anticancer compounds - cytarabine (CT) and ferric carboxymaltose (FC) (Fe+3) in Wistar rats.


METHODS
The Wistar rats were treated as follows: group 1 (control), NaCl 0.9%; group 2, CT (25 mg/k), group 3, FC(Fe+3) (50 mg/k) and group 4, CT + FC(Fe+3). The animals were sacrificed and their brains were obtained and used to measure lipoperoxidation (TBARS), H2O2, Na+, K+ ATPase, glutathione (GSH), serotonin metabolite (5-HIAA) and dopamine. The results indicated an enhancement of lipid peroxidation in the cortex and striatum of groups treated with FC(Fe+3) and CT, while GSH decreased in the cortex of group treated with CT + FC(Fe+3). Dopamine decreased in the cortex of the rats that received CT, while in the striatum, 5HIAA increased in all groups.


RESULTS & CONCLUSION
These results suggest that the treatment with CT and FC(Fe+3) boosted oxidative stress and led to an alteration in momoamine concentrations in the brain.
['Guzmán|David Calderón|DC|', 'Brizuela|Norma Osnaya|NO|', 'Herrera|Maribel Ortíz|MO|', 'Olguín|Hugo Juárez|HJ|', 'Peraza|Armando Valenzuela|AV|', 'García|Ernestina Hernández|EH|', 'Jiménez|Francisca Trujillo|FT|', 'Mejía|Gerardo Barragán|GB|']
D000818:Animals D001921:Brain D003561:Cytarabine D004298:Dopamine D005290:Ferric Compounds D006861:Hydrogen Peroxide D015227:Lipid Peroxidation D008320:Maltose D010084:Oxidation-Reduction D018384:Oxidative Stress D017208:Rats, Wistar D012701:Serotonin
brain Iron anticancer agents malignant tumor oncological diseases oxidative damage.